-
Recordati: A Somehow Boring But Interesting Pharmaceutical Company
25 May 2018 00:24 GMT
… has shifted its traditional pharmaceutical business towards a more … a 15% CAGR decline.
Seloken/logimax: The franchise … is a latest generation statin indicated in the reduction … not tolerate the existing treatment. The drug is well tolerated per …
-
RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE
22 May 2017 06:03 GMT
… of the rights to Seloken®/Seloken® ZOK (metoprolol succinate) … of cardiac rhythm, maintenance treatment after myocardial infarction, and … is a widely used drug in all European … of medical representatives promotes a wide range of innovative pharmaceuticals, …
-
AstraZeneca PLC (AZN) CEO Pascal Soriot on Q4 2021 Results - Earning Call Transcript
11 Feb 2022 03:29 GMT
… 2022 and will include Seloken ZOK, Prilosec and [ … Pharmaceuticals. Eplontersen is in Phase III trials for the treatment … recently granted orphan drug designation by the FDA.
I will … growth from our innovative medicines, our robust internal pipeline …
-
RECORDATI: BOARD APPROVES THE 2017 ACCOUNTS. SALES € 1,288.1 MILLION (+11.6%), OPERATING INCOME € 406.5 MILLION (+24.1%) AND NET INCOME € 288.8 MILLION (+21.6%). 2017 DIVIDEND € 0.85 (+21.4%)
15 Mar 2018 11:18 GMT
… treatment is currently being investigated in a phase II clinical trial … rights to Seloken®/Seloken® ZOK ( … treatment of neurotrophic keratitis, which already received an Orphan Drug … medical representatives promotes a wide range of innovative pharmaceuticals …
-
RECORDATI: PRELIMINARY 2017 RESULTS CONFIRM CONTINUED GROWTH OF SALES AND PROFITABILITY. SALES +11.6%, OPERATING INCOME +24.1%, NET INCOME +21.6%
08 Feb 2018 11:26 GMT
… to Seloken®/Seloken® ZOK and Logimax®, metoprolol based cardiovascular treatments. … development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy … of medical representatives promotes a wide range of innovative pharmaceuticals, …
-
RECORDATI: VERY GOOD RESULTS IN THE FIRST NINE MONTHS 2017. CONTINUED GROWTH IN SALES +11.8%, OPERATING INCOME +21.8%, NET INCOME +20.6%. INTERIM DIVIDEND € 0.42 (+20%)
26 Oct 2017 10:02 GMT
… of the rights to Seloken®/Seloken® ZOK (metoprolol succinate … trials in over 1,800 patients and one long-term trial … , a novel drug for the treatment of schizophrenia is … medical representatives promotes a wide range of innovative pharmaceuticals, …
-
RECORDATI: VERY GOOD RESULTS IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%
27 Jul 2017 09:25 GMT
… treatment is currently being investigated in a phase II clinical trial … rights to Seloken®/Seloken® ZOK ( … treatment of neurotrophic keratitis, which already received an Orphan Drug … medical representatives promotes a wide range of innovative pharmaceuticals …
-
US Futures Slip, Asian Shares Gain on China Data: Markets Wrap
25 Jul 2024 06:20 GMT
… , manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway … , Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort …
About
© 1995-2025